Stratification of women according to the risk of developing breast cancer can improve screening and prevention by targeting those most likely to benefit. Polygenic risk scores (PRSs) summarizing the effect of common susceptibility variants facilitate such stratification, but the clinical utility of current PRSs is limited. Improved stratification may be obtained by increasing sample size, including sub-genome wide significant SNPs in the PRS and optimising for prediction of subtype specific disease.